Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Two years ago, as Iveric Bio went through late-stage studies of its main experimental drug, it began attracting interest from potential buyers. Five companies ended …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look